SCHEMBL29356384

SCHEMBL29356384

O=S(=O)(CCC(F)(F)F)Nc1ccc(Br)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.44
GRK2 P25098 1/20 0.44
RECQL P46063 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
BRAF P15056 1/20 0.41
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
LMNA P02545 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TP53 P04637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22190937 1.00 SMN1; SMN2 (0.44) SMN1; SMN2GRK2RECQLCTDSP1TDP1
SCHEMBL7876952 0.85 BRAF (0.45) TSHRKMT2APTGS1PTGS2BRAF
SCHEMBL20840389 0.82 CYP3A4 (0.55) SMN1; SMN2GRK2RECQLCTDSP1TDP1
SCHEMBL30566205 0.80 PSIP1 (0.59) SMN1; SMN2GRK2RECQLCTDSP1TDP1
SCHEMBL6221236 0.80 PSIP1 (0.59) SMN1; SMN2GRK2RECQLCTDSP1TDP1
SCHEMBL3988911 0.79 ALOX15 (0.45) SMN1; SMN2GRK2RECQLCTDSP1TDP1
SCHEMBL31568559 0.76 CA2 (0.62) SMN1; SMN2GRK2RECQLCTDSP1TDP1
SCHEMBL3019846 0.73 CYP3A4 (0.49) PTGS1PTGS2BRAFPSIP1CYP3A4
SCHEMBL1494488 0.73 PTGS1 (0.45) PTGS1PTGS2BRAFCA2PSIP1
SCHEMBL30526897 0.73 KMT2A (0.56) SMN1; SMN2GRK2RECQLCTDSP1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3941919-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES Genentech, Inc. (US) 2022-01-26 EP disclosed